In July 2025, this pharmaceutical company started its new phase of growth as a commercial entity, following the landmark approval of the first and only oral on-demand treatment for Hereditary Angioedema (HAE). With initial demand surpassing expectations, the company is confident that its HAE treatment has the potential to become a core therapy in HAE management.
The company we are profiling today is KalVista Pharmaceuticals Inc. (KALV), the developer of EKTERLY, the first and only oral on-demand treatment for hereditary angioedema.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com